Monitor the implementation date of the reverse split for near-term volatility. Post-split, the stock may experience selling pressure from holders exiting at higher nominal prices, but the reduced float could attract speculative interest if the company issues positive news. The split alone does not address the company's cash position or operational outlook.
Price Chart
Executive Summary
Virax Biolabs shareholders approved a 1-for-10 to 1-for-30 reverse stock split at an Extraordinary General Meeting marked by extremely low turnout (3.65% of shares). The split is intended to boost the per-share price, likely to maintain Nasdaq listing compliance, but does not change the company's weak fundamentals or $1M market cap.
Key Facts
- Shareholders approved a reverse stock split at a ratio between 1:10 and 1:30, with par value increasing from $0.001 to $0.01-$0.30.
- Only 3.65% of outstanding shares were present at the adjourned meeting; quorum was met by those present per Articles of Association.
- The initial meeting on June 5, 2026 failed to achieve quorum (3.6% turnout) and was adjourned to June 12, 2026.
- Votes on the reverse split: 517,694 for, 202,763 against, 5,951 abstain.
- Shareholders also approved amending the Articles of Association to reflect revised authorized share capital post-split.
Financial Impact
No financial figures cited; the split reduces outstanding shares by 90-97% but does not raise cash or change enterprise value.
Risk Factors
- Post-reverse split price decline typical of micro-cap stocks (often -20% to -40% in weeks following).
- Risk of Nasdaq delisting if the stock fails to maintain $1.00 bid price after the reverse split.
- Extremely low shareholder engagement (3.65% turnout) signals minimal retail or institutional support.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-268604 |
| Document: 0001193125-26-268604-index-headers.html | 0001193125-26-268604 |
| Document: 0001193125-26-268604-index.html | 0001193125-26-268604 |
| Document: 0001193125-26-268604.txt | 0001193125-26-268604 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $1.85 | awaiting T+60 | — | $1.19 (−35.68%) |
Sep 4, 2026 7w ago | 6-K | $2.63 | awaiting T+60 | — | $1.19 (+54.75%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 | awaiting T+60 | — | $1.19 (−54.67%) |
Aug 18, 2026 9w ago | 6-K | $2.76 | awaiting T+60 | — | $1.19 (−56.88%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $1.19 | ▲ +54.58% | ▲ +57.04% | $1.19 (+54.58%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $1.87 | ▼ −52.05% | ▼ −55.76% | $1.19 (−69.49%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.20 | ▲ +65.41% | ▲ +67.04% | $1.19 (+81.29%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.20 | ▼ −65.41% | ▼ −67.04% | $1.19 (−81.29%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.0924 | ▼ −31.56% | ▼ −36.89% | $1.19 (+781.48%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1092 | ▼ −40.65% | ▼ −43.44% | $1.19 (+546.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers